share_log

EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Hassan Fred

EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Hassan Fred

EyePoint Pharmaceuticals | 4：持股變動聲明-董事 Hassan Fred
美股SEC公告 ·  09/06 04:08
牛牛AI助理已提取核心訊息
EyePoint Pharmaceuticals, Inc. (EYPT) has reported a transaction involving Hassan Fred, a person associated with the company. The transaction took place on September 3, 2024. However, the specific details regarding the nature of the transaction, such as the number of shares involved and the transaction price, have not been disclosed. The relationship of Hassan Fred to the issuer was not specified in the announcement. Investors are advised to seek additional information to fully understand the impact of this transaction on their investment decisions.
EyePoint Pharmaceuticals, Inc. (EYPT) has reported a transaction involving Hassan Fred, a person associated with the company. The transaction took place on September 3, 2024. However, the specific details regarding the nature of the transaction, such as the number of shares involved and the transaction price, have not been disclosed. The relationship of Hassan Fred to the issuer was not specified in the announcement. Investors are advised to seek additional information to fully understand the impact of this transaction on their investment decisions.
EyePoint Pharmaceuticals, Inc.（EYPT）報告了一筆涉及到公司相關人士Hassan Fred的交易。該交易發生於2024年9月3日。然而，關於交易的具體細節，如涉及的股數和交易價格，並未披露。Hassan Fred與發行人的關係在公告中未作具體說明。建議投資者尋求額外信息，全面了解該交易對其投資決策的影響。
EyePoint Pharmaceuticals, Inc.（EYPT）報告了一筆涉及到公司相關人士Hassan Fred的交易。該交易發生於2024年9月3日。然而，關於交易的具體細節，如涉及的股數和交易價格，並未披露。Hassan Fred與發行人的關係在公告中未作具體說明。建議投資者尋求額外信息，全面了解該交易對其投資決策的影響。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間